Role of bridging RT in relapsed/refractory diffuse large B-cell lymphoma undergoing CAR-T therapy: a multicenter study.

Autor: Bramanti S; IRCCS Humanitas Research Hospital, Humanitas, Cancer Center, Milano, Rozzano Milano, Italy., Mannina D; IRCCS Humanitas Research Hospital, Humanitas, Cancer Center, Milano, Rozzano Milano, Italy. daniele.mannina@humanitas.it., Chiappella A; IRCCS Istituto Nazionale Tumori, Milano, Italy., Casadei B; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli', Bologna, Italy., De Philippis C; IRCCS Humanitas Research Hospital, Humanitas, Cancer Center, Milano, Rozzano Milano, Italy., Giordano L; IRCCS Humanitas Research Hospital, Humanitas, Cancer Center, Milano, Rozzano Milano, Italy., Navarria P; IRCCS Humanitas Research Hospital, Humanitas, Cancer Center, Milano, Rozzano Milano, Italy., Mancosu P; IRCCS Humanitas Research Hospital, Humanitas, Cancer Center, Milano, Rozzano Milano, Italy., Taurino D; IRCCS Humanitas Research Hospital, Humanitas, Cancer Center, Milano, Rozzano Milano, Italy., Scorsetti M; IRCCS Humanitas Research Hospital, Humanitas, Cancer Center, Milano, Rozzano Milano, Italy., Carlo-Stella C; IRCCS Humanitas Research Hospital, Humanitas, Cancer Center, Milano, Rozzano Milano, Italy., Zinzani P; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli', Bologna, Italy.; Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy., Santoro A; IRCCS Humanitas Research Hospital, Humanitas, Cancer Center, Milano, Rozzano Milano, Italy.; Dept. of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milano, Italy., Corradini P; IRCCS Istituto Nazionale Tumori, Milano, Italy.
Jazyk: angličtina
Zdroj: Bone marrow transplantation [Bone Marrow Transplant] 2024 Oct 09. Date of Electronic Publication: 2024 Oct 09.
DOI: 10.1038/s41409-024-02427-8
Abstrakt: The optimization of bridging regimen before chimeric antigen receptor (CAR)-T cell therapy in diffuse large B-cell lymphoma (DLBCL) may impact CAR-T efficacy and outcome. This retrospective study evaluates CAR-T outcome after bridging with radiotherapy (RT) and other bridging strategies. Among 148 patients with relapsed/refractory DLBCL who underwent leukapheresis for CAR-T manufacturing, 31 received RT-bridging, 84 chemotherapy (CT), 33 no-bridging or steroid-only. CAR-T cell were infused in 96.8% of RT-group, 89.2% of CT-group and 78.8% of no-bridge-group (p = 0.079). Response to bridging was generally poor, but patients receiving RT had a significant reduction in LDH levels between pre- and post-bridging (p = 0.05). The one-year PFS was 51.2% in the RT-group, 28.2% in the CT-group, and 47.6% in the no-bridge-group (p = 0.044, CT-bridging vs RT-bridging); 1-year OS was 86.7% in the RT-group, 52.7% in the CT-group and 69% in the no-bridge-group (p = 0.025, CT-bridging vs RT-bridging). We observed a higher incidence of ICANS in patients who received CT than in others (20.0% CT-group, 3.3% RT-group, 7.7% no-bridge group; p = 0.05). In conclusion, RT-bridging is associated with lower drop-out rate and CAR-T toxicity, and it might be preferred to other bridging strategies for patients with localized disease or for those with one prevalent symptomatic site.
(© 2024. The Author(s), under exclusive licence to Springer Nature Limited.)
Databáze: MEDLINE
Externí odkaz: